These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 19049379

  • 1. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD, Pellicano F, Scaramuzza A, Sardu C, Casetti T, Bosi E, Miselli V, Brandolini S, Fabbri T, Meandri P, Cannatà F.
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [Abstract] [Full Text] [Related]

  • 2. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW, Johnson JA, Hyveled L, Tamer SC, Demissie M.
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [Abstract] [Full Text] [Related]

  • 3. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM, Insulin Aspart Pediatric Pump Study Group.
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.
    Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR.
    Diabetes Care; 2002 Nov; 25(11):2053-7. PubMed ID: 12401756
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A, Jacobsen LV.
    Clin Pharmacokinet; 2001 Nov; 40(9):641-59. PubMed ID: 11605714
    [Abstract] [Full Text] [Related]

  • 13. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.
    Diabetes Metab Res Rev; 2004 Nov; 20(1):55-60. PubMed ID: 14737746
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
    Hermansen K, Colombo M, Storgaard H, ØStergaard A, Kølendorf K, Madsbad S.
    Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
    [Abstract] [Full Text] [Related]

  • 17. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP.
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [Abstract] [Full Text] [Related]

  • 18. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R.
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [Abstract] [Full Text] [Related]

  • 19. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
    Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR.
    Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
    [Abstract] [Full Text] [Related]

  • 20. Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.
    Griffen SC, Oostema K, Stanhope KL, Graham J, Styne DM, Glaser N, Cummings DE, Connors MH, Havel PJ.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):485-91. PubMed ID: 16317063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.